+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications



Topical mitomycin C chemotherapy in the management of ocular surface neoplasia: a 10-year review of treatment outcomes and complications



British Journal of Ophthalmology 94(10): 1316-1321



The use of topical mitomycin C (MMC) has gained popularity in the management of ocular surface neoplasia. The aim of this study is to determine outcomes and complications following such treatment. This study is a retrospective review of patients treated with topical MMC for ocular surface neoplasia, including primary acquired melanosis (PAM), melanoma, corneal-conjunctival intraepithelial neoplasia (CCIN), squamous cell carcinoma (SCC) and sebaceous gland carcinoma (SGC). Data regarding diagnosis, short- and long-term outcomes, and short- and long-term complications, were recorded. 58 patients were identified, with a mean age of 63 years and mean follow-up of 36 months. 21 received MMC as primary therapy and 37 as surgical adjuvant. The regimen was 0.04% MMC four times a day for 3 weeks on, 3 weeks off, 3 weeks on, with topical steroid and lubricants throughout. Initial clinical response was either partial or complete in 93%. Overall, 26% developed recurrent disease at a mean of 13 months post treatment. Recurrence rates by pathology were 20% PAM, 25% melanoma, 0% CCIN, 67% SCC and 57% SGC. Short-term complications occurred in 52%, but only 7% required treatment cessation. Long-term complications such as persisting keratoconjunctivitis, epiphora and corneal problems, occurred in 31%. The results confirm the effectiveness of topical MMC chemotherapy in the management of ocular surface neoplasia. Self-limiting short-term complications were common; however, limbal stem cell deficiency appears to be a significant long-term complication of treatment, occurring in 12%.

(PDF emailed within 0-6 h: $19.90)

Accession: 056605535

Download citation: RISBibTeXText

PMID: 20530655

DOI: 10.1136/bjo.2009.176099


Related references

Management of diffuse ocular surface squamous neoplasia: efficacy and complications of topical chemotherapy. Clinical & Experimental Ophthalmology 43(1): 20-25, 2015

Topical Mitomycin-C Chemotherapy in Ocular Surface Squamous Neoplasia. Journal of Clinical and Diagnostic Research 10(9): Nj01-Nj01, 2016

Long-term outcomes after adjunctive topical 5-flurouracil or mitomycin C for the treatment of surgically excised localised ocular surface squamous neoplasia. 2013

Long-term outcomes after adjunctive topical 5-flurouracil or mitomycin C for the treatment of surgically excised localised ocular surface squamous neoplasia. 2013

Long-term outcomes after adjunctive topical 5-flurouracil or mitomycin C for the treatment of surgically excised, localized ocular surface squamous neoplasia. Clinical & Experimental Ophthalmology 42(4): 317-322, 2014

Topical mitomycin C for treatment of intraepithelial neoplasia of the ocular surface. IOVS 40(4): S336, March 15, 1999

Topical mitomycin-C for treatment of partially-excised ocular surface squamous neoplasia. Archives of Iranian Medicine 12(1): 55-59, 2009

Tear function and ocular surface changes with topical mitomycin (MMC) treatment for primary corneal intraepithelial neoplasia. Cornea 22(7): 627-639, 2003

Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b. American Journal of Ophthalmology 157(2): 287-293.E2, 2014

Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. British Journal of Ophthalmology 90(7): 819-822, 2006

Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification. Archives of Ophthalmology 130(2): 159-164, 2012

Randomized controlled trial of topical mitomycin C for ocular surface squamous neoplasia: early resolution. Ophthalmology 114(5): 976-982, 2007

Topical chemotherapy for ocular surface squamous neoplasia. Current Opinion in Ophthalmology 24(4): 336-342, 2013

Ocular surface squamous neoplasia: evidence for topical chemotherapy. International Ophthalmology Clinics 55(1): 9-21, 2015

Topical chemotherapy for ocular surface squamous neoplasia: current status. British Journal of Ophthalmology 94(5): 532-535, 2010